The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Improving treatment options for patients with R/R myeloma: immunotherapies & CELMoDs
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares some insights into how the treatment and management of relapsed/refractory (R/R) multiple myeloma has progressed over the years, highlighting the role of novel immunotherapies in improving outcomes for patients. Dr Popat then goes on to discuss promising results emerging with the use of the cereblon E3 ligase modulators (CELMoDs) iberdomide and mezigdomide, and where these may fit in the treatment armamentarium. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
